NHRI researchers report resident vs. non-resident human multipotent mesenchymal stromal/stem cell (MSC) interactions with B lymphocytes result in disparate outcomes


Multipotent human mesenchymal stromal/stem cells (MSCs) from multiple organs including the bone marrow (BM) and placenta (P‐MSCs) harbor clinically relevant immunomodulation best demonstrated toward T lymphocytes. Surprisingly, little in known on its interactions with B lymphocytes, which originate from the BM where there is a resident MSC. Dr. B. Linju Yen from the Institute of Cellular and System Medicine and collaborators therefore evaluated the interactions of both types of MSCs against human and mouse B lymphocytes in in vitro and in vivo studies with findings published in Stem Cells Translational Medicine (2021 Jan 28. doi: 10.1002/sctm.20-0289).

Dr. Yen and team found that P‐MSCs but not BM‐MSCs significantly inhibit proliferation and further differentiation of stimulated human peripheral B populations in vitro. Moreover, although BM‐MSCs preserve multiple IL‐10‐producing regulatory B cell (Breg) subsets, P‐MSCs significantly increase all subsets. To corroborate these in vitro findings in vivo, the team used a mouse model of B‐cell activation and found that adoptive transfer of P‐MSCs but not BM‐MSCs significantly decreased activated B220+ B cells. Moreover, adoptive transfer of P‐MSCs but not BM‐MSCs significantly decreased the overall B220+ B‐cell proliferation and further differentiation, similar to the in vitro findings. P‐MSCs also increased two populations of IL‐10‐producing murine Bregs more strongly than BM‐MSCs. Transcriptome analyses demonstrated multifactorial differences between BM‐ and P‐MSCs in the profile of relevant factors involved in B lymphocyte proliferation and differentiation. These results not only highlight the differential and global interactions of diverse human MSC sources with peripheral B lymphocytes, but also demonstrate the importance of understanding MSC tissue‐specific differences to achieve more effective therapeutic outcome

Citation: Lee, W; Wang, LT; Yen, ML; Hsu, PJ; Lee, YW; Liu, KJ; Lin, KI; Su, YW; Sytwu, HK; Yen, BL. Resident vs nonresident multipotent mesenchymal stromal cell interactions with B lymphocytes result in disparate outcomes. Stem Cells Translational Medicine. 2021 Jan 28;Article in Press

Comments are closed.